002030 達安基因
按盤價 
7.100 +0.040 (+0.567%)
7.100 +0.040 (+0.567%) | 2025/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 169,137 | -14.71% | 853,024 | 1,180,897 | 12,046,135 | 7,664,262 | |
| 減：營業總成本 | 238,176 | 14.53% | 1,058,065 | 1,133,441 | 5,191,468 | 3,600,398 | |
| 其中:營業成本 | 116,640 | 33.18% | 532,743 | 584,929 | 3,271,535 | 1,934,079 | |
| 財務費用 | (10,286) | -36.06% | (65,069) | (74,749) | (111,036) | (30,813) | |
| 資產減值損失 | (3,491) | -6,515.58% | (75,040) | (262,754) | (681,999) | (19,243) | |
| 公允價值變動收益 | 200,727 | -154.91% | (175,746) | 435,691 | 82,321 | (83,779) | |
| 投資收益 | (24,753) | 12.02% | (253,838) | (26,247) | 271,184 | 219,125 | |
| 其中：對聯營企業和合營企業的投資收益 | (26,136) | 1.05% | (271,331) | (46,101) | 129,360 | 164,859 | |
| 營業利潤 | 93,177 | -121.50% | (1,067,605) | 121,622 | 6,329,254 | 4,125,397 | |
| 利潤總額 | 93,829 | -121.62% | (1,071,163) | 113,536 | 6,318,937 | 4,120,081 | |
| 減：所得稅費用 | 42,566 | -158.37% | (132,051) | 41,804 | 891,378 | 501,595 | |
| 淨利潤 | 51,263 | -114.19% | (939,113) | 71,732 | 5,427,558 | 3,618,487 | |
| 減：非控股權益 | (1,661) | -177.29% | (13,943) | (32,928) | 15,217 | 300 | |
| 股東淨利潤 | 52,924 | -114.57% | (925,170) | 104,660 | 5,412,341 | 3,618,187 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.040 | -115.38% | -0.660 | 0.070 | 3.857 | 2.578 | |
| 每股派息 (元) * | -- | -- | -- | 0.015 | 1.750 | 1.110 | |
| 每股淨資產 (元) * | 5.652 | -6.86% | 5.615 | 6.327 | 8.052 | 5.238 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 14/08/2025 11:52 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
